Myelin oligodendrocyte glycoprotein-specific B-cell receptor (MOG-specific BCR) (MOG-specific BCR)

The Myelin Oligodendrocyte Glycoprotein (MOG)-specific B-cell receptor is a membrane-bound immunoglobulin that specifically recognizes MOG, a protein localized to the outermost surface of myelin sheaths in the central nervous system (Reindl & Waters, 2019, Lancet Neurology). In pathological states such as MOG Antibody-Associated Disease (MOGAD) and certain experimental models of Multiple Sclerosis, B-cells expressing this receptor escape central and peripheral tolerance (Jarius et al., 2018, J Neuroinflammation). These autoreactive B-cells contribute to disease by acting as professional antigen-presenting cells that activate T-cells and by differentiating into plasma cells that secrete pathogenic anti-MOG antibodies (Mendel et al., 1995, Eur J Immunol). These antibodies facilitate demyelination through complement activation and recruitment of effector cells. Therapeutic targeting of the MOG-specific BCR, such as with the investigational agent ANK-700, aims to induce immune tolerance or selectively deplete these pathogenic clones without the broad immunosuppression associated with general B-cell therapies (Anokion, 2023). This approach is designed to reprogram the immune system to ignore MOG while maintaining normal responses to infections. The specificity for the MOG35-55 epitope is particularly relevant in the Experimental Autoimmune Encephalomyelitis (EAE) model, which serves as a primary tool for studying demyelinating diseases (Johns et al., 1995, J Immunol).

Other names

Anti-MOG B-cell receptorMOG35-55-reactive B-cell receptorMOG-specific surface immunoglobulinMOG-autoantibody-producing B-cell receptor

Antigen-specific immune tolerance induction or selective depletion of autoreactive B-cells